Early and sustained increase in time in range 1 year after initiation of hybrid close loop therapy via telemedicine in type 1 diabetes patients.

Publication Year: 2023

DOI:
10.1007/s00592-023-02051-w

PMCID:
PMC10068726

PMID:
37010594

Journal Information

Full Title: Acta Diabetol

Abbreviation: Acta Diabetol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Endocrinology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Conflict of interestAMG reports speaker fees from Novo Nordisk, Sanofi, Elli Lilly, Boehringer Ingelheim, Abbott and Medtronic. DCH reports speaker fees from Novo Nordisk, Sanofi, Medtronic and Abbott. Ethical Standard StatementThe protocol was approved by the ethics and research committee of the Pontificia Universidad Javeriana and the Hospital Universitario San Ignacio. Informed consentAll patients filled out informed consent. Conflict of interest AMG reports speaker fees from Novo Nordisk, Sanofi, Elli Lilly, Boehringer Ingelheim, Abbott and Medtronic. DCH reports speaker fees from Novo Nordisk, Sanofi, Medtronic and Abbott."

Evidence found in paper:

"Funding Open Access funding provided by Colombia Consortium."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025